Poly (ADP-ribose) polymerase (PARP): Rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Orlando, Laura ^a   Schiavone, Paola ^a   Fedele, Palma ^a   Calvani, Nicola ^a   Nacci, Angelo ^a   Cinefra, Margherita ^a   D'Amico, Maria ^a   Mazzoni, Enrica ^a   Marino, Antonella ^a   Sponziello, Francesco ^a   Morelli, Franco ^b   Lombardi, Lucia ^b   Silvestris, Nicola ^c   Cinieri, Saverio ^a,d  

^a Ospedale A Perrino   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

DNA repair; Poly(ADP ribose) polymerase (PARP) inhibitors; triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLAPARIB; VELIPARIB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DOSE ESCALATION; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SINGLE STRANDED DNA BREAK;

ANIMALS; BREAST NEOPLASMS; DNA REPAIR; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84858975438     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.648925     Document Type: Article

References (47)

1. Kim MY, Zhang T, Kraus WL. Poly (ADP-ribosyl)ation by PRP-1:"PAR-laying"NAD+ into a nuclear signal. Genes Dev 2005;19:1951-67 (Pubitemid 41247953)
2. Schreiber V, Dantzer F, Ame JC, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-52 Explanations of the broad spectrum of activity of PARP.
3. D'Amours D, Desnoyers S, Silva D, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68 (Pubitemid 29425344)
4. Rojo F, Garcia-Parra J, Zazo S, et al. Nuclear PARP-1 protein overxepression is associated with poor overall survival in early breast cancer. Ann Oncol 2011: published online 9 September 2011; doi:10.1093/annonc/mdr361
5. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74 (Pubitemid 32467046)
6. Lieber MR. The mechanism of double-strand DNA break repair by non homologous DNA end-joining pathway. Ann Rev Biochem 2010;79:181-211
7. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864-74 The role of BRCA in DNA stability. (Pubitemid 44453442)
8. Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates RAD 51 mediated recombination. Nature 2010;467:678-83
9. Rouleau M, Patel A, hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10(4):293-301 The role of components of PARP family.
10. Saxena A, Wong LH, Kalitsis P, et al. Poly(ADP-ribose)polymerase 2 localizes to mammalian active centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub3, but not Cenpc. Hum Mol Genet 2002;11:2319-29
11. Dobzhansky T. Genetics of natural populations. XIII. Recombination and variability in population of Drosophila pseudoobscura. Genetics 1946;31:269-90
12. Drablos F, Feyzi E, Aas PA, et al. Alkylation damage in DNA and. RNA-repair mechanism and medical significance. DNA Repair (Amst) 2004;3:1389-407 (Pubitemid 39221738)
13. Rodon J, Iniesta MD, Papadopoulos K, et al. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009;18:31-43
14. Brody LC. Treating cancer by targeting a weakness. N Engl J Med 2005;353:949-50 (Pubitemid 41247939)
15. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancer deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90
16. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17 The mechanism of synthetic lethality. (Pubitemid 40559005)
17. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategies. Nature 2005;434:917-21 (Pubitemid 40559006)
18. Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008;13:395-400 Role of BRCA1 in sporadic cancer.
19. Venkitaram AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82
20. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204 (Pubitemid 351301852)
21. Krishnakumar R, Kraus WL. PARP1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell 2010;39(5):736-49
22. Frizzell KM, Gamble MJ, Berrocal JG. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J Biol Chem 2009;284(49):33926-39
23. Pavri R, Lewis B, Kim TK, et al. PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of Mediator. Mol Cell 2005;18:83-96; polymerase and protects eroded telomers
24. Dantzer F, Giraud-Panis MJ, Jaco I, et al. Functional interaction between poly (ADP-ribose) polymerase 2(PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol Cell Biol 2004;24:1595-607
25. Gomez M, Wu J, Schreiber V, et al. PARP-1 is a TRF2-associated poly(ADP-ribose) polymerase and protects eroded telomeres. Mol Biol Cell 2006;17:1686-96 (Pubitemid 44011586)
26. Ohki R, Ishikawa F. Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats. Nucleic Acid Res 2004;32:1627-37 (Pubitemid 38832708)
27. Beneke S, Cohausz O, Malang M, et al. Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1. Nucleic Acid Res 2008;19:6309-17
28. Pyriochou A, Olah G, Deitch E, et al. Inhibition of angiogenesis by the poly (AD-ribose) polymerase inhibitor PJ-34. Int J Mol Med 2008;22:113-18
29. Tentori L, Lacal PM, Muzi A, et al. Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007;43:2124-33 (Pubitemid 47380363)
30. Cepeda V, Fuertes MA, Castilla J, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov 2006;1:39-53
31. Fong PC, Boss Ds, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-43 Activity of PARP inhibitors in BRCA-dependent cancers.
32. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA 2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44 Activity of PARP inhibitors in BRCA-dependent breast cancers.
33. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple- negative breast cancer: a phase 2, multicenter, open-label, non randomized-study. Lancet Oncol 2011;12:852-61 Activity of PARP inhibitors in ovarian and breast cancers.
34. Kummar S, Kinders R, Gutierrex ME, et al. Phase 0 clinical trial of the poly (ADP-ribose)polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;26:2705-11
35. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine and cisplatin. Cancer Res 2010;70:7970-80
36. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple negative breast cancer. N Engl J Med 2011;364:205-14 Clinical activity of PARP inhibitors in randomized Phase II trial for triple-negative breast cancer.
37. O'Shaughnessy J. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple negative breast cancer. J Clin Oncol 2011;29-81(Suppl):abstract 1007
38. Hay T, Jenkins H, Sansom OJ, et al. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005;65:10145-8 (Pubitemid 41743700)
39. Williamsin CT, Muzik H, Turhan AG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010;9:347-57
40. Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutation in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68:2581-6 (Pubitemid 351556255)
41. Sakai W, Swuisher EM, Karlan BY, et al. Secondary mutation as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20 (Pubitemid 351317449)
42. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105:17079-84
43. Domagala P, Huzarski T, Lubinski J, et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011;127:861-9
44. Ji J, Lee MP, Kadota M, et al. Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD 2281, and BSI201 [abstract 4527]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2-6 April 2011; Orlando, FL Mechanism of action of different PARP inhibitors.
45. Feng Z, Zhang J. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest. Nucleic Acid Res 2010;38:10661-1070
46. Efimova EV, Mauceri HJ, Golden DW, et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 2010;70:6277-92
47. Beneke R, Moroy T. Inhibition of poly (ADP-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice. Oncogene 2001;20:8136-41 (Pubitemid 34028338)